Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 6/20 | 0.78 |
| ▸ | HEXB | P07686 | 6/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | RGS12 | O14924 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11678428 | 0.98 | HEXA (0.76) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL11807201 | 0.98 | HEXA (0.76) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL4187947 | 0.95 | HEXA (0.81) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL9626265 | 0.91 | HEXA (0.83) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL9625779 | 0.90 | HEXA (0.81) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL9625395 | 0.90 | HEXA (0.81) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL9625535 | 0.90 | HEXA (0.81) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL9625518 | 0.90 | HEXA (0.81) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL4997995 | 0.88 | HEXA (1.00) | HEXAHEXBALDH1A1KDM4EKMT2A | |
| SCHEMBL17718739 | 0.85 | ALDH1A1 (0.69) | HEXAHEXBALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103864685-B | A kind of fluorescent probe and the application in detection ferrous ion thereof | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-21 | — | — | CN | claimed |
| CN-103864685-A | Fluorescent probe and application thereof in detection of divalent iron ions | DALIAN CHEMICAL PHYSICS INST | 2014-06-18 | — | — | CN | claimed |
| US-4006238-A | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents | E. R. SQUIBB & SONS, INC. (US) | 1977-02-01 | — | — | US | claimed |
| US-20240224999-A1 | METABOLIC INHIBITORS FOR CONTROLLING BIOFILM | MC US 3 LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240224999-A1 | METABOLIC INHIBITORS FOR CONTROLLING BIOFILM | MC US 3 LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230183640-A1 | METABOLIC INHIBITORS WITH EFFICACY FOR INHIBITING SULFIDE PRODUCTION IN HARSH ENVIRONMENTS | LANXESS CORPORATION | 2023-06-15 | — | — | US | disclosed |
| US-20230183640-A1 | METABOLIC INHIBITORS WITH EFFICACY FOR INHIBITING SULFIDE PRODUCTION IN HARSH ENVIRONMENTS | LANXESS CORPORATION | 2023-06-15 | — | — | US | disclosed |
| EP-0612324-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993009136-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1993-05-13 | — | — | WO | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-4006238-A | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents | E. R. SQUIBB & SONS, INC. (US) | 1977-02-01 | — | — | US | disclosed |
| US-3940397-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-02-24 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240224999-A1 | METABOLIC INHIBITORS FOR CONTROLLING BIOFILM | RIMKLA, HDHD5, SCD | HEXA 453/4885HEXB 393/4885ALDH1A1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.